• Rezolute announced preliminary results showing ersodetug met the primary efficacy endpoint in its Phase 3 upLIFT study in tumor hyperinsulinism.
• Most participants discontinued intravenous glucose, reducing dependence on treatment for low blood sugar.
• Ersodetug was well tolerated, with no drug-related safety findings to date.
• Full study results, including statistical analysis of the primary endpoint, are expected by mid-December 2026.
• FDA discussions are planned for the first quarter of 2027 as the company seeks approval for congenital and tumor hyperinsulinism.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rezolute Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611130618PRIMZONEFULLFEED9877147) on November 13, 2026, and is solely responsible for the information contained therein.